Dubai, UAE: – Cellogique Corporation is pleased to announce a newly established partnership with Dansys Medical & Aesthetic Equipment LLC. Cellogique Corporation has appointed Dansys as the exclusive distributor of Obagi Medical Products in the United Arab Emirates.

Mr. Jamil Maalouf, Chief Executive Officer of Dansys, said, “At Dansys, we are committed to delivering a complete and comprehensive solution to our customers which entails offering top of the range products for their every need. Obagi’s legacy and track record in skin care are a testament to their quality and it is Dansys’ aim to support their penetration and coverage across the region. It goes without saying that we are excited to add Obagi to Dansys’ portfolio and are confident of the success we can achieve together across the UAE.”

“We are thrilled to be partnering with Dansys as our new distributors in the UAE. Their expansive reach across the UAE and their complimentary portfolio of products, technologies, and equipment ensure that the partnership will be a success. I’m confident that we are putting the Obagi brand in capable hands that will take its distribution to the next level,” shared Mr. Mazen Youssef, Cellogique Corporation’s president and CEO.

-Ends-

About Dansys Medical & Aesthetic Equipment LLC

Dansys Medical & Aesthetic Equipment LLC is a privately-owned company founded in 2007, headquartered in Dubai, UAE. With over 40 top tier brands across plastic surgery, dermatology, aesthetics, radiology, and gynecology - Dansys has grown to become the leading Medical & Aesthetics distributor in the region. As the industry pioneer, Dansys has introduced breakthrough technologies across verticals and continues to offer a versatile and comprehensive portfolio of products from selective and best in class network of global manufacturers.

Dansys Medical & Aesthetic Equipment – Headquartered in Dubai, UAE

About Cellogique Corporation

Cellogique Corporation has been pioneering the world of cosmetic surgery, medical aesthetics, and skin health for several years throughout the Middle East region. Cellogique Corporation’s innovative approach on medical aesthetics led to the concept and development of Obagi MediSpas. Cellogique Corporation and Obagi MediSpas are committed to providing the best in cosmetic treatments, procedures, and products that are both effective and safe. As a leader in aesthetic medicine, Obagi MediSpas provide skin health restoration according to the Obagi philosophy to create and maintain healthy skin for all patients. 

The state-of-the-art facilities of Obagi MediSpas offer the very best in aesthetic medicine, from restorative and therapeutic treatments to the latest laser technologies. Obagi MediSpas provide patients of any age and skin type with cutting edge services that focus on skin health and overall wellness. Obagi MediSpas boast a clean, chic, and comfortable environment to accommodate every patient. 

Cellogique Corporation and Obagi MediSpas carefully select an expert team of dermatologists and cosmetic and plastic surgeons trained in the United States under the world-renowned Dr. Suzan Obagi. The physicians and highly skilled healthcare professionals are well equipped to provide the world-class care and guidance necessary to achieve healthy skin and overall wellness.

Cellogique Corporation – Headquartered in Pittsburgh, Pennsylvania, USA cellogique.com

About Obagi

Obagi Cosmeceuticals, LLC is an industry-leading, advanced skin care line formulated with scientifically proven ingredients and refined with a legacy of 30 years' experience. First known as leaders in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi products are designed to restore your skin's natural radiance by visibly improving balance, tone and texture, and diminishing the appearance of premature aging, photodamage, skin discoloration, acne and sun damage.

Obagi Cosmeceuticals LLC – Headquartered in Long Beach, California, USA

For press enquiries, please contact Snehman Kohli at snehman@creosconsulting.com 

© Press Release 2019

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.